Table 3. Associations between different combined groups of clinical and genetic factors and disease-free survival (DFS) among breast cancer patients.
| Discovery set | Replication set | |||||
|---|---|---|---|---|---|---|
| HR a | (95% CI) | P | HR a | (95% CI) | P | |
| Group by RPA among HR+ HER2- breast cancer patients | ||||||
| Group 1: TNM stage 0-II and rs166870CC+CT | 1.00 | ref. | 1.18×10-8 | 1.00 | ref. | 2.08×10-5 |
| Group 2: TNM stage 0-II and rs166870TT | 5.52 | (2.00–15.28) | 2.01 | (0.90–4.47) | ||
| Group 3: TNM stage III and rs166870CC+CT | 3.61 | (2.29–5.68) | 3.07 | (0.64–14.83) | ||
| Group 4: TNM stage III and rs166870TT | 10.50 | (1.43–77.06) | 7.26 | (2.95–17.88) | ||
| Group by RPA among HR- HER2- breast cancer patients | ||||||
| Group1: rs10825036TT+TG | 1.00 | ref. | 2.35×10-4 | 1.00 | ref. | 2.60×10-2 |
| Group2: rs10825036GG | 3.45 | (1.78–6.67) | 2.17 | (1.10–4.28) | ||
Abbreviations: DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; RPA, recursive partitioning analysis; HR, hormone receptor; HER2, human epidermal growth factor receptor 2.
aCox proportional hazard model adjusted for age and recruiting center, additional TNM stage for group by tumor subtypes and selected SNPs.